CSP
VRTX icon

Cary Street Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Cary Street Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Buy
22,571
+104
+0.5% +$46.1K 0.25% 96
2026
Q1 		$10M Buy
22,467
+112
+0.5% +$52.2K 0.25% 93
2025
Q4 		$10.1M Sell
22,355
-568
-2% -$245K 0.25% 91
2025
Q3 		$8.98M Sell
22,923
-586
-2% -$245K 0.23% 105
2025
Q2 		$10.5M Sell
23,509
-197
-0.8% -$90.8K 0.29% 86
2025
Q1 		$11.5M Sell
23,706
-183
-0.8% -$85.3K 0.36% 70
2024
Q4 		$9.62M Buy
+23,889
New +$11.1M 0.31% 83

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Cary Street Partners's VRTX Position: Q2 2026 in Review

Cary Street Partners increased its Vertex Pharmaceuticals (VRTX) stake by 0.46% in Q2 2026, buying an estimated $46.1K and bringing the position to 22,571 shares worth $11.2M. The position accounts for 0.25% of the portfolio, ranked #96.

Cary Street Partners first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.5M in Q1 2025. 296 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Cary Street Partners held 22,571 shares of Vertex Pharmaceuticals worth $11.2M as of Q2 2026.
  • Cary Street Partners bought 104 Vertex Pharmaceuticals shares in Q2 2026, an estimated $46.1K.
  • Vertex Pharmaceuticals made up 0.25% of Cary Street Partners's portfolio in Q2 2026, its #96 holding.
  • Cary Street Partners first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Cary Street Partners's Vertex Pharmaceuticals position peaked at $11.5M in Q1 2025.
  • 296 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.